<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515032</url>
  </required_header>
  <id_info>
    <org_study_id>SF-C002</org_study_id>
    <nct_id>NCT02515032</nct_id>
  </id_info>
  <brief_title>Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia</brief_title>
  <official_title>A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed With Non Small Cell Lung Cancer (NSCLC) With Involuntary Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smartfish AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smartfish AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SF-C002 is a pilot study in patients with newly diagnosed NSCLC suffering from involuntary
      weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective
      is to study the safety and tolerability of Nutrifriend Cachexia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study.
      The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in
      patients with NSCLC. The secondary objectives of the study are to evaluate effects on body
      composition, muscle function, daily activity, inflammation, tumor growth, compliance,
      appetite and Quality of Life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessed by (adverse events, concomitant medication and laboratory markers) of Nutrifriend Cachexia in patients with NSCLC</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by fat mass and lean body mass (LBM)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by weight</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by BMI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by waist circumference</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition assessed by calf circumference</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by 6 minute walking test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by grip strength</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function assessed by walking distance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>IL-6, IL-8, TNF-alpha, CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glucose, insulin, cholesterol, HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by EORTC QLQ-C3</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed by Nutrition Appetite Questionnaire (CNAQ)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by Drinks consumed</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by vitamin D levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance assessed by Omega-3 incorporation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Response to chemotherapy by tumor growth</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers related to cachexia, e.g. carnosine, beta-alanine</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Cachexia</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>NF Cachexia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An isocaloric placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrifriend Cachexia</intervention_name>
    <description>2 daily for 12 weeks</description>
    <arm_group_label>NF Cachexia</arm_group_label>
    <other_name>NFCax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Isocaloric placebo</intervention_name>
    <description>2 daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placobo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-line standard chemotherapy as curative or palliative treatment for NSCLC

          -  Will start the first cycle of standard chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

          -  Involuntary weight loss

        Exclusion Criteria:

          -  Another invasive malignancy in the last 2 years.

          -  Previous relapse of NSCLC within 2 years of randomisation

          -  Other cachectic disorders such as renal or hepatic disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Muscaritoli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Sapienza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GH Varaždin</name>
      <address>
        <city>Varaždin</city>
        <zip>42 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH Zadar</name>
      <address>
        <city>Zadar</city>
        <zip>23 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Zagreb,</name>
      <address>
        <city>Zagreb</city>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico di Roma</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00151</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP F.D. Roosvelta Banská Bystrica</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica Sv. Jakuba</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Východoslovenský onkologický ústav</name>
      <address>
        <city>Košice</city>
        <zip>041 91</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NsP Štefana Kukuru Michalovce</name>
      <address>
        <city>Michalovce</city>
        <zip>071 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP J.A. Reimana</name>
      <address>
        <city>Prešov</city>
        <zip>081 81</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linkoping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

